Background: inflammatory chemokines such as CCL2 and CCL5 are involved in the progress of osteoarthritis. Crocin with antioxidant and anti-inflammatory properties can reduce the symptoms of osteoarthritis (OA). This study was performed investigate the effect of Krocina™, on the gene expressions and plasma levels of CCL2 and CCL5 in OA patients. Methods: The study included 35 patients that we...

Osteoarthritis (OA) is the most prevalent joint disease, considered rheumatic condition with greatest consequences in terms of socioeconomic impacts, especially knee osteoarthritis since it makes walking difficult. To date, there no cure for OA, so available treatments aim to reduce symptoms such as pain and inflammation, maintain mobility, limit loss function. As OA has a known inflammatory co...

Biomechanical factors and physical examination findings in osteoarthritis of the knee: associations with tissue abnormalities assessed by conventional radiography and high-resolution 3 T magnetic resonance imaging Abstract Introduction. We aimed to explore the associations between knee osteoarthritis (OA)-related tissue abnormalities assessed by conventional radiography (CR) and high resolution...

INTRODUCTION Treatment of osteoarthritis (OA) continues to be primarily based on symptom modification. The concept of disease modification for OA has been proposed and potential drugs are in the pipeline. Hylan G-F 20 (Synvisc) is an FDA-approved hyaluronate derivative which is administered by injection into osteoarthritic joints for treating pain associated with osteoarthritis. The present stu...

Osteoarthritis (OA) is a chronic degenerative joint disease and a major health problem in the elderly population. No disease-modifying osteoarthritis drug (DMOAD) has been made available for clinical use. Here we present a disease-modifying strategy for OA, focusing on messenger RNA (mRNA) delivery of a therapeutic transcription factor using polyethylene glycol (PEG)-polyamino acid block copoly...

Quantitative measures of cartilage morphology (i.e., thickness) represent potentially powerful surrogate endpoints in osteoarthritis (OA). These can be used to identify risk factors of structural disease progression and can facilitate the clinical efficacy testing of structure modifying drugs in OA. This paper focuses on quantitative imaging of articular cartilage morphology in the knee, and wi...

INTRODUCTION: Knee osteoarthritis (OA) is a major source of morbidity in the aging population with a prevalence of over 16% in people older than 45. Prior studies typically define OA progression in terms of joint space narrowing or cartilage loss measured from radiographs or MRI. However, these methods do not directly capture the impact of OA on the patient Direct measures of OA on the symptoms...

Osteoarthritis (OA) is one of the most common forms of degenerative joint disease and a major cause of pain and disability affecting the aging population. It is estimated that more than 20 million Americans and 35 to 40 million Europeans suffer from OA. Analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) are the only therapeutic treatment options for OA. Effective pharmacotherapy for ...

Osteoarthritis (OA) is a degenerative disease characterized by thinning of the joint cartilage and is associated with disability and pain. A large portion of the cases are age-related – progressive overloading of the cartilage, as well as the reduced abilities of the body to regenerate with age, result in cartilage lesions and joint inflammation [5]. Osteoarthritis can also occur after a single...